arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces today that it has entered into an ...
arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed its ...
Dental gold producer Argen has acquired the worldwide exclusive manufacturing and distribution rights for all Captek products and technologies, the company announced. "We believe that Argen's vast ...
"At Zimbis, we're driven by the opportunity to make complex operations simpler for dental laboratories," said Louis Visser, President Zimbis. "By partnering with Argen, we're giving labs access to ...
RuiYi (formerly Anaphore) negotiated a worldwide exclusive license to ArGEN-X’ preclinical anti-IL-6 monoclonal antibody ARGX-109, which is in development as a potential treatment for oncology and ...
Lonza and arGEN-X N.V. have announced that they have entered into a new, multi-product commercial license agreement for the production of arGEN-X’s therapeutic antibodies. The license secures ...
CYPRESS, Texas—Argen Polymer L.L.C., a specialist in materials development, consulting, testing and analysis, has moved into a new 15,000-sq.-ft. facility in Cypress. The 5-year-old company moved to ...
ARGEN is a patented light scattering instrument that addresses key research and development issues in the biopharmaceutical industry by providing real-time stability monitoring, manufacturing stress ...
Fluence Analytics announced the launch of ARGEN, a patented protein and polymer stability monitoring product. By utilizing continuous light scattering measurements, ARGEN yields a unique information ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results